Podocyte-Targeted AAV Vector for Local Complement Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for complement-mediated kidney diseases, such as C3 glomerulopathy and IgA Nephropathy, face challenges due to the high concentration of complement proteins in circulation and the risk of systemic side effects, including increased susceptibility to infections, particularly with systemic complement inhibitors.
Innovation Solution
A viral vector targeting podocytes, specifically an AAV vector with a podocyte-specific promoter, is used to deliver complement inhibitors like CFI, CFH, or FHL-1, ensuring localized regulation of the complement system within the kidney, thereby reducing systemic side effects and enhancing treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic complement inhibitors are used to treat complement-mediated kidney diseases, then disease progression is reduced, but susceptibility to infections with encapsulated organisms increases
Solution Approach 1:
The patent applies local quality by using a podocyte-specific promoter to restrict complement inhibitor expression to podocytes only, rather than systemically. This creates localized complement regulation in the kidney glomerulus, reducing disease progression in the affected tissue while avoiding widespread immunosuppression that would increase infection susceptibility.
Solution Approach 2:
The invention segments the complement inhibition function by delivering complement inhibitors specifically to podocytes through a podocyte-targeted viral vector system. This divides the systemic complement regulation into a localized podocyte-specific function, thereby treating kidney disease without the broad side effects of systemic inhibition.
2Productivity
If high concentration of complement inhibitors is administered to effectively regulate the complement system, then treatment efficacy is improved, but systemic side effects and toxicity increase
Solution Approach 1:
The patent achieves localized high concentration of complement inhibitors specifically within podocytes through the podocyte-specific promoter, providing effective local complement regulation without requiring high systemic concentrations. This local concentration approach maintains treatment efficacy in the kidney while avoiding systemic toxicity.
Solution Approach 2:
The viral vector serves as an intermediary delivery mechanism that transports complement inhibitor genes specifically to podocytes. This intermediary system enables precise delivery of therapeutic material to the target cell type, achieving effective local treatment without the harmful effects of systemic administration.
3Reliability
If complement inhibitors are delivered systemically to treat kidney disease, then disease progression is reduced, but the complexity of treatment monitoring and management increases
Solution Approach 1:
By restricting complement inhibitor expression to podocytes through the podocyte-specific promoter, the treatment monitoring becomes simpler and more direct. Clinicians can focus monitoring on kidney-specific outcomes rather than managing complex systemic effects, reducing the overall complexity of treatment monitoring and management.
Data Source
AI summary
The present invention provides a viral vector comprising a nucleotide sequence encoding a complement protein, wherein the nucleotide sequence is operably linked to a podocyte-specific promoter and/or the viral vector is capable of specifically transducing podocytes.